INTEGRATING GENOMICS AND TRANSCRIPTOMICS TO RESHAPE PRECISION ONCOLOGY:
|
|||
Saturday 29 October 2022 |
|||
WELCOME AND OPENING REMARKS |
|||
|
Welcome and Opening Remarks |
Richard L. Schilsky |
Chairman WIN Consortium, Villejuif, France |
Josep Tabernero |
Vice-Chairman WIN Consortium, Villejuif, France |
||
|
Opening Keynote Lecture Re-imagining the (r)evolution in the Precision Oncology paradigm: the future is now |
Vivek Subbiah |
The University of Texas, MD Anderson Cancer Center, Houston, USA |
SESSION 1 - BEYOND DNA TESTING: THE PLACE OF TRANSCRIPTOMICS IN PRECISION ONCOLOGY |
|||
|
Keynote Lecture Expression profiling to discover molecularly and clinically distinct cancer subtypes and to predict response to therapy |
Louis M. Staudt |
National Cancer Institute (NCI), Bethesda, USA |
|
Keynote Lecture Functional genomics to identify cancer vulnerabilities |
René Bernards |
Netherlands Cancer Institute (NKI), Amsterdam, Netherlands |
|
Accelerating precision oncology using multi-omics and AI |
Olivier Elemento |
Weill Cornell Medicine, New York, USA |
Coffee break, networking |
|||
|
Modeling gene regulatory processes to understand cancer and identify therapies |
John Quackenbush |
Harvard T.H. Chan School of Public Health, Boston, USA |
![]() |
SIMS and Digital Display Precision Predictor algorithms |
Vladimir Lazar |
WIN Consortium, Villejuif, France |
|
Harnessing a synthetic lethality analysis for patient stratification: key role of transcriptomics |
Eytan Ruppin |
National Institute of Health (NIH), Bethesda, USA |
Panel Discussion |
|||
Lunch, poster viewing and networking |
|||
SESSION 2 – INNOVATION IN CLINICAL TRIALS TO ENABLE FUTURE EFFICIENT TREATMENTS |
|||
|
Keynote opening Lecture Bringing single cell analyses to the clinics |
Andrea Califano |
Columbia University Medical Center, New York, USA |
|
Keynote lecture Identifying new uses for approved, targeted drugs: Updates from the ASCO TAPUR study |
Richard L. Schilsky |
WIN Consortium, Villejuif, France |
|
Genomic and transcriptomic signatures and innovation in CRC |
Josep Tabernero |
Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
|
Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: comprehensive tumor genomic and transcriptomic analyses |
Jean-François Martini |
Pfizer, Inc., San Diego, USA |
|
Patient stratification/selection for treatments with Tepotinib in |
Ilhan Celik |
Merck KGaA, Darmstadt, Germany |
Coffee break, networking |
|||
Satellite Symposium |
|||
Poster viewing Welcome Reception |
|||
Symposium Dinner |
Download the WIN 2022 Program

WIN 2022 Symposium
c/o MCI UK Ltd
Durford Mill
Petersfield
GU31 5AZ
Tel: +44 (0) 1730 715223
General enquiries: winsymposium@mci-group.com
Sponsorship enquiries: winsymposium@mci-group.com
Abstract enquiries: winsympabstracts@mci-group.com
Registration enquiries: winsympreghot@mci-group.com